Last updated: February 21, 2026
What is the Drug?
NDC 00378-6614 corresponds to Venclexta (venetoclax), developed by AbbVie. It is an oral BCL-2 inhibitor indicated primarily for chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and certain other hematologic malignancies. Approved by the FDA in 2016, Venclexta has since expanded its indications.
Market Overview
Indications and Approved Uses
- Chronic lymphocytic leukemia (CLL) with or without 17p deletion.
- Small lymphocytic lymphoma (SLL).
- Acute myeloid leukemia (AML) in combination with azacitidine or decitabine for patients ineligible for intensive chemotherapy (FDA approved in 2020).
Market Size and Penetration
Estimate the U.S. market:
| Parameter |
Estimate |
Source/Notes |
| U.S. CLL incidence |
Approximately 20,000 new cases annually |
[1] |
| U.S. SLL incidence |
Similar to CLL, total > 20,000 cases |
[1] |
| Total eligible patients (treatment) |
Approx. 15,000 (assuming 70%) |
Based on treatment rates, disease progression, eligibility [2] |
| Market penetration (initial) |
50% in 2016, rising to 75% by 2021 |
Adoption rate of targeted therapies [3] |
Competitive Landscape
- Ibrutinib (Imbruvica): Dominated the CLL market since 2013, with sales surpassing $6 billion annually.
- Acalabrutinib (Calquence): Entered later, capturing a significant segment since 2019.
- Venetoclax (Venclexta): Gained rapid market share, especially post-2016 approval, due to favorable efficacy data and convenient oral dosing.
Key Market Players
- AbbVie (Venclexta)
- Johnson & Johnson (Imbruvica)
- AstraZeneca (Calquence)
- Pfizer (Venclexta distribution partnerships)
Price Analysis
Current Pricing
- Average wholesale price of Venclexta: ~$13,500 per month (per 100 mg tablet, FDA label recommends 400 mg daily maintenance dose).
- Annual cost: approximately $162,000 per patient.
Price Trends
- Initial launch price (2016): ~$13,000/month.
- Price adjustments have been marginal, with minor discounts and rebates.
- Compound annual growth rate (CAGR) for drug price: approximately 1-2% since launch, consistent with industry inflation trends.
Comparative Pricing
| Drug |
Monthly Cost |
Indication |
Market Share (2022) |
Notes |
| Venclexta |
$13,500 |
CLL, SLL, AML |
45% |
Leading targeted oral agent in hematology |
| Imbruvica |
$15,000 |
CLL, MCL, Waldenström's macroglobulinemia |
40% |
Slightly more expensive, broader indications |
| Calquence |
$14,500 |
CLL, MCL |
10% |
Newer, gaining popularity |
Revenue Projections
Assumptions
- Market share growth: 70% penetration among eligible patients by 2024.
- Patient count in the U.S.: 15,000.
- Average treatment duration: 12 months for initial responders.
- Pricing: steady at ~$13,500/month.
Revenue Estimates
| Year |
Patients Treated |
Monthly Price |
Annual Revenue (U.S. only) |
| 2023 |
10,500 |
$13,500 |
~$1.7 billion |
| 2024 |
11,250 |
$13,500 |
~$1.8 billion |
| 2025 |
12,000 |
$13,500 |
~$2.0 billion |
Key Factors Impacting Revenue
- Patent status: No immediate generics expected until 2028, maintaining exclusivity.
- Line extension opportunities: Potential for new formulations or indications could boost sales.
- Pricing power: Limited due to biosimilar/generic threats and payer pressure.
Price Projection Outlook
- Medium-term: Stable pricing with annual increases of 1-2% due to inflation and market dynamics.
- Long-term (post-patent expiration): Declines of 50-70% expected within 3-5 years after patent expiry, comparable to other oncology agents.
Regulatory and Market Risks
- Patent challenges: Patent expirations around 2028 could introduce biosimilars.
- Market competition: Increased approval and adoption of alternative therapies (e.g., BTK inhibitors).
- Pricing pressures: Payer negotiations and value-based care models could limit future price increases.
Summary
Venclexta maintains a leading role in hematological malignancy treatment, with current annual U.S. sales near $1.7 billion. Its steady price point and expanding indications suggest modest growth, supported by increased patient access and ongoing clinical adoption. Expected patent protection supports stable pricing until at least 2028, after which significant price declines are forecast post-patent expiry.
Key Takeaways
- Venclexta’s U.S. market exceeds $1.7 billion annually, driven by expanding indications and increasing patient treatment rates.
- Pricing remains stable around $13,500/month, with minimal fluctuations.
- Long-term revenue growth depends on market share retention and new indication approvals.
- Patent protection extends until approximately 2028, after which biosimilar competition could significantly reduce prices.
- Market and pricing risks stem from intense competition, patent challenges, and payer pressures.
Frequently Asked Questions
1. When does Venclexta face patent expiration?
Patent expiry is projected around 2028, after which biosimilars may enter the market.
2. How does Venclexta compare price-wise with rivals?
It is slightly less expensive than Imbruvica but more costly than emerging biosimilars post-2028.
3. What are the main drivers of market growth?
Indication expansion, increased adoption in AML, and growing patient access.
4. Will prices decline before patent expiration?
Potentially, due to increasing biosimilar competition and payer negotiations, but current trends show stable pricing.
5. How significant is the AML indication for future sales?
It provides a growth avenue post-2020, with a targeted patient base of approximately 5,000 in the U.S., and could substantially contribute to revenue if adoption accelerates.
References
[1] American Cancer Society. (2022). Cancer Facts & Figures.
[2] National Cancer Institute. (2020). Hematologic malignancies.
[3] IQVIA. (2022). Oncology market report.
